Literature DB >> 16010416

Establishment of a new human epithelioid sarcoma cell line, FU-EPS-1: molecular cytogenetic characterization by use of spectral karyotyping and comparative genomic hybridization.

Jun Nishio1, Hiroshi Iwasaki, Kazuki Nabeshima, Masako Ishiguro, Sabine Naumann, Teruto Isayama, Masatoshi Naito, Yasuhiko Kaneko, Masahiro Kikuchi, Julia A Bridge.   

Abstract

A small number of human epithelioid sarcoma cell lines have been reported, but their characterization at a molecular cytogenetic level is not well known. In this study, a new permanent human cell line, FU-EPS-1, derived from a metastatic epithelioid sarcoma developing in the axillary lymph node of a 21-year-old man is described. This cell line was characterized by use of immunocytochemistry, conventional G-banding analysis, spectral karyotyping (SKY) and comparative genomic hybridization (CGH). FU-EPS-1 cells were round, polygonal or spindle shaped with an abundant cytoplasm, and have been maintained continuously in vitro for over 100 passages during more than 15 months. Histologic features of the heterotransplanted tumors in severe combined immunodeficiency mice were essentially the same as those of the original tumor, revealing a multinodular proliferation of eosinophilic epithelioid and spindle cells. Both in vitro and in vivo, the cells were immunopositive for cytokeratins (AE1/AE3 and CAM5.2), epithelial membrane antigen, vimentin and CD34, but were negative for desmin, S-100 protein, CD31 or factor VIII-related antigen. By G-banding and SKY analyses, FU-EPS-1 revealed a hyperdiploid karyotype with the following chromosomal abnormalities: +i(5)(p10), -8, +13, der(13)t(8;13)(q?;p11), +der(19)t(9;19)(?;?) and del(22)(q13). In addition, CGH analysis identified gains of 5p, 9q, 19q and 22q and a loss of 8p. This study demonstrates the value of molecular cytogenetic techniques such as SKY and CGH in defining genomic alterations in greater detail. The FU-EPS-1 cell line will be exceedingly useful for biologic and molecular pathogenetic studies of human epithelioid sarcoma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16010416

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  5 in total

1.  Serum CA 125 expression as a tumor marker for diagnosis and monitoring the clinical course of epithelioid sarcoma.

Authors:  Makiko Hoshino; Hiroyuki Kawashima; Akira Ogose; Naoko Kudo; Takashi Ariizumi; Tetsuo Hotta; Hajime Umezu; Hiroshi Hatano; Tetsuro Morita; Jyun Nishio; Hiroshi Iwasaki; Naoto Endo
Journal:  J Cancer Res Clin Oncol       Date:  2009-09-16       Impact factor: 4.553

Review 2.  Epithelioid Sarcoma: Opportunities for Biology-Driven Targeted Therapy.

Authors:  Jonathan Noujaim; Khin Thway; Zia Bajwa; Ayeza Bajwa; Robert G Maki; Robin L Jones; Charles Keller
Journal:  Front Oncol       Date:  2015-08-17       Impact factor: 6.244

3.  Synthetic emmprin peptides with chitobiose substitution stimulate MMP-2 production by fibroblasts.

Authors:  Takehito Kawakami; Tetsuro Sameshima; Hironobu Hojo; Kaori Koga; Yoshiaki Nakahara; Bryan P Toole; Junji Suzumiya; Yasunori Okada; Akinori Iwasaki; Kazuki Nabeshima
Journal:  BMC Cancer       Date:  2011-07-17       Impact factor: 4.430

4.  A novel angiomatoid epithelioid sarcoma cell line, Asra-EPS, forming tumors with large cysts containing hemorrhagic fluid in vivo.

Authors:  Yoshinori Imura; Norifumi Naka; Hidetatsu Outani; Hirohiko Yasui; Satoshi Takenaka; Ken-ichiro Hamada; Ritsuro Ozaki; Mitsunori Kaya; Ken-ichi Yoshida; Eiichi Morii; Akira Myoui; Hideki Yoshikawa
Journal:  BMC Res Notes       Date:  2013-08-01

5.  High expression of CD109 antigen regulates the phenotype of cancer stem-like cells/cancer-initiating cells in the novel epithelioid sarcoma cell line ESX and is related to poor prognosis of soft tissue sarcoma.

Authors:  Makoto Emori; Tomohide Tsukahara; Masaki Murase; Masanobu Kano; Kenji Murata; Akari Takahashi; Terufumi Kubo; Hiroko Asanuma; Kazuyo Yasuda; Vitaly Kochin; Mitsunori Kaya; Satoshi Nagoya; Jun Nishio; Hiroshi Iwasaki; Tomoko Sonoda; Tadashi Hasegawa; Toshihiko Torigoe; Takuro Wada; Toshihiko Yamashita; Noriyuki Sato
Journal:  PLoS One       Date:  2013-12-20       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.